56
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Population pharmacokinetics of olprinone in healthy male volunteers

, , , , , , , & show all
Pages 43-50 | Published online: 04 Mar 2014

References

  • HonerjägerPPharmacology of bipyridine phosphodiesterase III inhibitorsAm Heart J19911216 Pt 2193919441852089
  • SkoylesJRSherryKMPharmacology, mechanisms of action and uses of selective phosphodiesterase inhibitorsBr J Anaesth19926832933021547054
  • KimataSHirosawaKKasanukiH[Clinical evaluation of E-1020 injection for acute heart failure. Study of acute effects by single intravenous infusion and intravenous drip]Jpn Clin Exp Med199269722602274 Japanese
  • MonradESBaimDSSmithHSLanoueASMilrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failureCirculation1986733 Pt 2III168III1743510773
  • AdachiHTanakaHEffects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failureJ Cardiovasc Pharmacol19972967637719234657
  • RathmellJPPrielippRCButterworthJFA multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgeryAnesth Analg19988646836909539583
  • OrimeYShionoMHataHEffects of phosphodiesterase inhibitors after coronary artery bypass graftingJpn Circ J199963211712210084374
  • TakaokaHTakeuchiMOdakeMComparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseases human heartJ Am Coll Cardiol19932225986068335835
  • AdachiHKamataSKodamaKNagakuraTVasorelaxant effect of a phosphodiesterase 3 inhibitor, olprinone, on isolated human radial arteryEur J Pharmacol20003961434710822053
  • GuarracinoFLapollaFCarielloCTarget controlled infusion: TCIMinerva Anestesiol200571633533715886597
  • ShortTGLimTATamYHProspective evaluation of pharmacokinetic model-controlled infusion of propofol in adult patientsBr J Anaesth19967623133158777118
  • Guidance for industry: population pharmacokineticsSilver Spring: United States Food and Drug Administration [updated 1999 Feb 1]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdfAccessed October 21, 2013
  • HookerACStaatzCEKarlssonMOConditional weighted residuals (CWRES): a model diagnostic for the FOCE methodPharm Res200724122187219717612795
  • TsubokawaTIshizukaSFukumotoKUenoKYamamotoKPopulation pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypassJ Anesth201327224325023090059
  • WietaschJKScholzMZinserlingJThe performance of a target-controlled infusion of propofol in combination with remifentanil: a clinical investigation with two propofol formulationsAnesth Analg2006102243043716428538
  • PassotSServinFAllaryRTarget-controlled versus manually-controlled infusion of propofol for direct laryngoscopy and bronchoscopyAnesth Analg200294512121216 table of contents11973192
  • De CastroVGodetGMenciaGRauxMCoriatPTarget-controlled infusion for remifentanil in vascular patients improves hemodynamics and decreases remifentanil requirementAnesth Analg2003961333812505919
  • VermeyenKMHoffmannVLSaldienVTarget controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic modelBr J Anaesth200390218318812538375
  • SugiokaMItoMMasuokaHIdentification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymesNaunyn Schmiedebergs Arch Pharmacol199435032842937824045
  • AraiTKamishimaKTerauchiT[Effects of olprinone hydrochloride in patients undergoing off-pump coronary artery bypass grafting]Masui2006552158163 Japanese16491891